Role of treatment for depressive symptoms in relieving the impact of fatigue in HIV-HCV co-infected patients: ANRS Co13 Hepavih, France, 2006-2008

Fatigue is a major component of quality of life (QOL) and is associated with depression in HIV–HCV co‐infected individuals. We investigated whether treating depressive symptoms (DS) could mitigate the impact of fatigue on daily functioning in co‐infected patients, even those at an advanced stage of...

Full description

Saved in:
Bibliographic Details
Published inJournal of viral hepatitis Vol. 17; no. 9; pp. 650 - 660
Main Authors Michel, L., Villes, V., Dabis, F., Spire, B., Winnock, M., Loko, M.-A., Poizot-Martin, I., Valantin, M. A., Bonnard, P., Salmon-Céron, D., Carrieri, M. P.
Format Journal Article
LanguageEnglish
Published Oxford, UK Blackwell Publishing Ltd 01.09.2010
Subjects
Adult
Antidepressive Agents - therapeutic use
CD4 antigen
Cognitive ability
Data collections
Data processing
Depression
Depression - drug therapy
Fatigue
Fatigue - drug therapy
Female
France
Hepatitis
hepatitis C
Hepatitis C, Chronic - complications
HIV Infections - complications
Human immunodeficiency virus
Humans
Infection
Inventories
Male
medical records
Middle Aged
Quality of life
Surveys and Questionnaires
Treatment Outcome
France
Online AccessGet full text

Cover

Abstract Fatigue is a major component of quality of life (QOL) and is associated with depression in HIV–HCV co‐infected individuals. We investigated whether treating depressive symptoms (DS) could mitigate the impact of fatigue on daily functioning in co‐infected patients, even those at an advanced stage of disease. The analysis was conducted on enrolment data of 328 HIV–HCV co‐infected patients recruited in the French nationwide ANRS CO 13 HEPAVIH cohort. Data collection was based on medical records and self‐administered questionnaires which included items on socio‐behavioural data, the fatigue impact scale (FIS) in three domains (cognitive, physical and social functioning), depressive symptoms (CES‐D classification) and use of treatments for depressive symptoms (TDS). After multiple adjustment for gender and unemployment, CD4 cell count <200 per mm3 was associated with a negative impact of fatigue on the physical functioning dimension (P = 0.002). A higher number of symptoms causing discomfort significantly predicted a higher impact of fatigue on all three dimensions (P < 0.001). This was also true for patients with DS receiving TDS when compared with those with no DS but receiving TDS. A significant decreasing linear trend (P < 0.001) of the impact of fatigue was found across the categories ‘DS/TDS’, ‘DS/no TDS’, ‘no DS/TDS’ and ‘no DS/no TDS’. Despite limitations related to the cross‐sectional nature of this study, our results suggest that routine screening and treatment for DS can reduce the impact of fatigue on the daily functioning of HIV–HCV co‐infected patients and relieve the burden of their dual infection.
AbstractList Fatigue is a major component of quality of life (QOL) and is associated with depression in HIV-HCV co-infected individuals. We investigated whether treating depressive symptoms (DS) could mitigate the impact of fatigue on daily functioning in co-infected patients, even those at an advanced stage of disease. The analysis was conducted on enrolment data of 328 HIV-HCV co-infected patients recruited in the French nationwide ANRS CO 13 HEPAVIH cohort. Data collection was based on medical records and self-administered questionnaires which included items on socio-behavioural data, the fatigue impact scale (FIS) in three domains (cognitive, physical and social functioning), depressive symptoms (CES-D classification) and use of treatments for depressive symptoms (TDS). After multiple adjustment for gender and unemployment, CD4 cell count <200 per mm3 was associated with a negative impact of fatigue on the physical functioning dimension (P = 0.002). A higher number of symptoms causing discomfort significantly predicted a higher impact of fatigue on all three dimensions (P < 0.001). This was also true for patients with DS receiving TDS when compared with those with no DS but receiving TDS. A significant decreasing linear trend (P < 0.001) of the impact of fatigue was found across the categories 'DS-TDS', 'DS-no TDS', 'no DS-TDS' and 'no DS-no TDS'. Despite limitations related to the cross-sectional nature of this study, our results suggest that routine screening and treatment for DS can reduce the impact of fatigue on the daily functioning of HIV-HCV co-infected patients and relieve the burden of their dual infection.
Fatigue is a major component of quality of life (QOL) and is associated with depression in HIV-HCV co-infected individuals. We investigated whether treating depressive symptoms (DS) could mitigate the impact of fatigue on daily functioning in co-infected patients, even those at an advanced stage of disease. The analysis was conducted on enrollment data of 328 HIV-HCV co-infected patients recruited in the French nationwide ANRS CO 13 HEPAVIH cohort. Data collection was based on medical records and self-administered questionnaires which included items on socio-behavioural data, the fatigue impact scale (FIS) in three domains (cognitive, physical and social functioning), depressive symptoms (CES-D classification) and use of treatments for depressive symptoms (TDS). After multiple adjustment for gender and unemployment, CD4 cell count &lt;200 per mm(3) was associated with a negative impact of fatigue on the physical functioning dimension (P = 0.002). A higher number of symptoms causing discomfort significantly predicted a higher impact of fatigue on all three dimensions (P &lt; 0.001). This was also true for patients with DS receiving TDS when compared with those with no DS but receiving TDS. A significant decreasing linear trend (P &lt; 0.001) of the impact of fatigue was found across the categories 'DS/TDS', 'DS/no TDS', 'no DS/TDS' and 'no DS/no TDS'. Despite limitations related to the cross-sectional nature of this study, our results suggest that routine screening and treatment for DS can reduce the impact of fatigue on the daily functioning of HIV-HCV co-infected patients and relieve the burden of their dual infection.
Fatigue is a major component of quality of life (QOL) and is associated with depression in HIV-HCV co-infected individuals. We investigated whether treating depressive symptoms (DS) could mitigate the impact of fatigue on daily functioning in co-infected patients, even those at an advanced stage of disease. The analysis was conducted on enrollment data of 328 HIV-HCV co-infected patients recruited in the French nationwide ANRS CO 13 HEPAVIH cohort. Data collection was based on medical records and self-administered questionnaires which included items on socio-behavioural data, the fatigue impact scale (FIS) in three domains (cognitive, physical and social functioning), depressive symptoms (CES-D classification) and use of treatments for depressive symptoms (TDS). After multiple adjustment for gender and unemployment, CD4 cell count <200 per mm(3) was associated with a negative impact of fatigue on the physical functioning dimension (P = 0.002). A higher number of symptoms causing discomfort significantly predicted a higher impact of fatigue on all three dimensions (P < 0.001). This was also true for patients with DS receiving TDS when compared with those with no DS but receiving TDS. A significant decreasing linear trend (P < 0.001) of the impact of fatigue was found across the categories 'DS/TDS', 'DS/no TDS', 'no DS/TDS' and 'no DS/no TDS'. Despite limitations related to the cross-sectional nature of this study, our results suggest that routine screening and treatment for DS can reduce the impact of fatigue on the daily functioning of HIV-HCV co-infected patients and relieve the burden of their dual infection.
Author Spire, B.
Salmon-Céron, D.
Villes, V.
Dabis, F.
Winnock, M.
Loko, M.-A.
Poizot-Martin, I.
Valantin, M. A.
Bonnard, P.
Michel, L.
Carrieri, M. P.
Author_xml – sequence: 1
  givenname: L.
  surname: Michel
  fullname: Michel, L.
  organization: INSERM U669, Paris, France
– sequence: 2
  givenname: V.
  surname: Villes
  fullname: Villes, V.
  organization: INSERM, U912 (SE4S), Marseille, France
– sequence: 3
  givenname: F.
  surname: Dabis
  fullname: Dabis, F.
  organization: INSERM U897, ISPED, Université Victor Segalen, Bordeaux, France
– sequence: 4
  givenname: B.
  surname: Spire
  fullname: Spire, B.
  organization: INSERM, U912 (SE4S), Marseille, France
– sequence: 5
  givenname: M.
  surname: Winnock
  fullname: Winnock, M.
  organization: INSERM U897, ISPED, Université Victor Segalen, Bordeaux, France
– sequence: 6
  givenname: M.-A.
  surname: Loko
  fullname: Loko, M.-A.
  organization: INSERM U897, ISPED, Université Victor Segalen, Bordeaux, France
– sequence: 7
  givenname: I.
  surname: Poizot-Martin
  fullname: Poizot-Martin, I.
  organization: CHU Sainte Marguerite, Marseille, France
– sequence: 8
  givenname: M. A.
  surname: Valantin
  fullname: Valantin, M. A.
  organization: CHU de la Pitié Salpétrière, Paris, France
– sequence: 9
  givenname: P.
  surname: Bonnard
  fullname: Bonnard, P.
  organization: Hôpital Tenon, Paris, France
– sequence: 10
  givenname: D.
  surname: Salmon-Céron
  fullname: Salmon-Céron, D.
  organization: Université Paris-Sud et Université Paris Descartes, UMR-S0669, Paris, France
– sequence: 11
  givenname: M. P.
  surname: Carrieri
  fullname: Carrieri, M. P.
  organization: INSERM, U912 (SE4S), Marseille, France
BackLink https://www.ncbi.nlm.nih.gov/pubmed/20002565$$D View this record in MEDLINE/PubMed
BookMark eNqFkctu1DAUhi1URG-8AvKOTZP6EueCxKIakaaoakULg8TG8sTHrYfcGnuGmdfoE-Mw7Wzxwj7S-b6jI__H6KDrO0AIUxLTcM6XMeWpiFhe8JgRUsSEMsbjzRt0tG8cTLVgEREkOUTHzi0JoZwJ-g4dBocwkYoj9HzXN4B7g_0IyrfQeWz6EWsYRnDOrgG7bTv4vnXYdniExsLadg_YPwK27aBqP8lGefuwggmpruZRNZvjuo9sZ6D2oPEQ2mGy-4Qvbu7u8aynHFcwqLV9PMPlqLoaznDYKY3ClZ-it0Y1Dt6_vCfoR_nl-6yKrm8vr2YX15HlPOGREgtGgSbaKL5ImS5YLYzgSUJMYQpBE8YJ0cYUqQClqSZZZhTNuSFc54Kk_AR93M0dxv5pBc7L1roamkZ10K-czESSFynPk_-TAWRZWmSB_PBCrhYtaDmMtlXjVr5-eAA-74A_toHtvk-JnIKVSznlJ6f8JqeQ_4KVG_l1Xk1V8KOdb52Hzd5X42-ZZjwT8ufNpSxFmZS_vs1lxf8Ct6mkpg
ContentType Journal Article
Contributor Bicart-See, A
Carrieri, P
Gillet, S
Almasi, F
Poizot-Martin, I
Paradis, V
Bonnard, P
Boufassa, F
Allain, L
Malet, M
Valantin, M A
Izopet, J
Costagliola, D
Pradier, C
Gervais, A
Meyer, L
Katlama, C
Neau, D
Louis, I
Kurkdji, P
Bentata, M
Breau, S
Beniken, D
See, A Bicart
Fontaine, H
Rosenthal, E
Eldbouni, O
Spiridon, G
Dominguez, S
Barange, K
Combes, C Lascoux
Girard, P M
Goujard, C
Raymond, I
Ivanova, A
Lascoux-Combe, C
Loko, M A
Autran, B
Solas, C
Krivitzky, A
Metivier, S
Merchadou, L Dequae
Mora, Marion
Frosch, A
Villes, V
Pialoux, G
Serini, L
Duvivier, C
Uzan, M
Cohen, J
Vittecoq, D
Boucly, S
Winnock, M
Fooladi, A
BaniSadr, F
Bani-sadr, F
Roque, A M
Lortholary, O
Chêne, G
Séréni, D
Bolliot, C
Morlat, P
Trimoulet, P
Pambrun, E
Lacombe, K
Dabis, F
Sogni, P
Azar, M
Delaune, J
Maignan, A
Garipuy, D
Salmon, D
Zaegel, O
Spire, B
Yéni, P
Mole, M
Benhamou, Y
Gastaut, J A
Honoré, P
Marchou, B
Delfraissy, J F
Contributor_xml – sequence: 1
  givenname: D
  surname: Salmon
  fullname: Salmon, D
– sequence: 2
  givenname: F
  surname: Dabis
  fullname: Dabis, F
– sequence: 3
  givenname: M
  surname: Winnock
  fullname: Winnock, M
– sequence: 4
  givenname: M A
  surname: Loko
  fullname: Loko, M A
– sequence: 5
  givenname: P
  surname: Sogni
  fullname: Sogni, P
– sequence: 6
  givenname: Y
  surname: Benhamou
  fullname: Benhamou, Y
– sequence: 7
  givenname: P
  surname: Trimoulet
  fullname: Trimoulet, P
– sequence: 8
  givenname: J
  surname: Izopet
  fullname: Izopet, J
– sequence: 9
  givenname: V
  surname: Paradis
  fullname: Paradis, V
– sequence: 10
  givenname: B
  surname: Spire
  fullname: Spire, B
– sequence: 11
  givenname: P
  surname: Carrieri
  fullname: Carrieri, P
– sequence: 12
  givenname: C
  surname: Katlama
  fullname: Katlama, C
– sequence: 13
  givenname: G
  surname: Pialoux
  fullname: Pialoux, G
– sequence: 14
  givenname: I
  surname: Poizot-Martin
  fullname: Poizot-Martin, I
– sequence: 15
  givenname: B
  surname: Marchou
  fullname: Marchou, B
– sequence: 16
  givenname: E
  surname: Rosenthal
  fullname: Rosenthal, E
– sequence: 17
  givenname: A Bicart
  surname: See
  fullname: See, A Bicart
– sequence: 18
  givenname: M
  surname: Bentata
  fullname: Bentata, M
– sequence: 19
  givenname: A
  surname: Gervais
  fullname: Gervais, A
– sequence: 20
  givenname: C
  surname: Lascoux-Combe
  fullname: Lascoux-Combe, C
– sequence: 21
  givenname: C
  surname: Goujard
  fullname: Goujard, C
– sequence: 22
  givenname: K
  surname: Lacombe
  fullname: Lacombe, K
– sequence: 23
  givenname: C
  surname: Duvivier
  fullname: Duvivier, C
– sequence: 24
  givenname: D
  surname: Vittecoq
  fullname: Vittecoq, D
– sequence: 25
  givenname: D
  surname: Neau
  fullname: Neau, D
– sequence: 26
  givenname: P
  surname: Morlat
  fullname: Morlat, P
– sequence: 27
  givenname: F
  surname: BaniSadr
  fullname: BaniSadr, F
– sequence: 28
  givenname: L
  surname: Meyer
  fullname: Meyer, L
– sequence: 29
  givenname: F
  surname: Boufassa
  fullname: Boufassa, F
– sequence: 30
  givenname: S
  surname: Dominguez
  fullname: Dominguez, S
– sequence: 31
  givenname: B
  surname: Autran
  fullname: Autran, B
– sequence: 32
  givenname: A M
  surname: Roque
  fullname: Roque, A M
– sequence: 33
  givenname: C
  surname: Solas
  fullname: Solas, C
– sequence: 34
  givenname: H
  surname: Fontaine
  fullname: Fontaine, H
– sequence: 35
  givenname: G
  surname: Chêne
  fullname: Chêne, G
– sequence: 36
  givenname: D
  surname: Costagliola
  fullname: Costagliola, D
– sequence: 37
  givenname: L
  surname: Allain
  fullname: Allain, L
– sequence: 38
  givenname: Marion
  surname: Mora
  fullname: Mora, Marion
– sequence: 39
  givenname: G
  surname: Spiridon
  fullname: Spiridon, G
– sequence: 40
  givenname: F
  surname: Almasi
  fullname: Almasi, F
– sequence: 41
  givenname: O
  surname: Eldbouni
  fullname: Eldbouni, O
– sequence: 42
  givenname: M A
  surname: Valantin
  fullname: Valantin, M A
– sequence: 43
  givenname: J A
  surname: Gastaut
  fullname: Gastaut, J A
– sequence: 44
  givenname: O
  surname: Zaegel
  fullname: Zaegel, O
– sequence: 45
  givenname: P
  surname: Bonnard
  fullname: Bonnard, P
– sequence: 46
  givenname: F
  surname: Bani-sadr
  fullname: Bani-sadr, F
– sequence: 47
  givenname: K
  surname: Barange
  fullname: Barange, K
– sequence: 48
  givenname: S
  surname: Metivier
  fullname: Metivier, S
– sequence: 49
  givenname: C
  surname: Pradier
  fullname: Pradier, C
– sequence: 50
  givenname: A
  surname: Krivitzky
  fullname: Krivitzky, A
– sequence: 51
  givenname: M
  surname: Uzan
  fullname: Uzan, M
– sequence: 52
  givenname: A
  surname: Bicart-See
  fullname: Bicart-See, A
– sequence: 53
  givenname: D
  surname: Garipuy
  fullname: Garipuy, D
– sequence: 54
  givenname: P
  surname: Yéni
  fullname: Yéni, P
– sequence: 55
  givenname: D
  surname: Séréni
  fullname: Séréni, D
– sequence: 56
  givenname: C Lascoux
  surname: Combes
  fullname: Combes, C Lascoux
– sequence: 57
  givenname: P M
  surname: Girard
  fullname: Girard, P M
– sequence: 58
  givenname: J F
  surname: Delfraissy
  fullname: Delfraissy, J F
– sequence: 59
  givenname: O
  surname: Lortholary
  fullname: Lortholary, O
– sequence: 60
  givenname: S
  surname: Boucly
  fullname: Boucly, S
– sequence: 61
  givenname: I
  surname: Raymond
  fullname: Raymond, I
– sequence: 62
  givenname: I
  surname: Louis
  fullname: Louis, I
– sequence: 63
  givenname: D
  surname: Beniken
  fullname: Beniken, D
– sequence: 64
  givenname: A
  surname: Ivanova
  fullname: Ivanova, A
– sequence: 65
  givenname: A
  surname: Fooladi
  fullname: Fooladi, A
– sequence: 66
  givenname: M
  surname: Azar
  fullname: Azar, M
– sequence: 67
  givenname: P
  surname: Honoré
  fullname: Honoré, P
– sequence: 68
  givenname: S
  surname: Breau
  fullname: Breau, S
– sequence: 69
  givenname: L
  surname: Serini
  fullname: Serini, L
– sequence: 70
  givenname: M
  surname: Mole
  fullname: Mole, M
– sequence: 71
  givenname: M
  surname: Malet
  fullname: Malet, M
– sequence: 72
  givenname: C
  surname: Bolliot
  fullname: Bolliot, C
– sequence: 73
  givenname: J
  surname: Delaune
  fullname: Delaune, J
– sequence: 74
  givenname: A
  surname: Maignan
  fullname: Maignan, A
– sequence: 75
  givenname: S
  surname: Gillet
  fullname: Gillet, S
– sequence: 76
  givenname: L Dequae
  surname: Merchadou
  fullname: Merchadou, L Dequae
– sequence: 77
  givenname: E
  surname: Pambrun
  fullname: Pambrun, E
– sequence: 78
  givenname: A
  surname: Frosch
  fullname: Frosch, A
– sequence: 79
  givenname: J
  surname: Cohen
  fullname: Cohen, J
– sequence: 80
  givenname: V
  surname: Villes
  fullname: Villes, V
– sequence: 81
  givenname: P
  surname: Kurkdji
  fullname: Kurkdji, P
Copyright 2009 Blackwell Publishing Ltd
Copyright_xml – notice: 2009 Blackwell Publishing Ltd
CorporateAuthor ANRS Co13 HEPAVIH Study Group
CorporateAuthor_xml – name: ANRS Co13 HEPAVIH Study Group
DBID BSCLL
CGR
CUY
CVF
ECM
EIF
NPM
7X8
7U9
H94
DOI 10.1111/j.1365-2893.2009.01223.x
DatabaseName Istex
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
Virology and AIDS Abstracts
AIDS and Cancer Research Abstracts
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
AIDS and Cancer Research Abstracts
Virology and AIDS Abstracts
DatabaseTitleList AIDS and Cancer Research Abstracts
MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Biology
EISSN 1365-2893
EndPage 660
ExternalDocumentID 20002565
JVH1223
ark_67375_WNG_F5F4FZQV_H
Genre article
Research Support, Non-U.S. Gov't
Journal Article
GeographicLocations France
GeographicLocations_xml – name: France
GroupedDBID ---
.3N
.GA
.GJ
.Y3
05W
0R~
10A
1OB
1OC
29L
31~
33P
36B
3SF
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5HH
5LA
5VS
66C
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AAJUZ
AAKAS
AANLZ
AAONW
AASGY
AAVGM
AAXRX
AAZKR
ABCQN
ABCUV
ABCVL
ABDBF
ABEML
ABHUG
ABJNI
ABPTK
ABPVW
ABQWH
ABXGK
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACGFO
ACGFS
ACGOF
ACMXC
ACPOU
ACPRK
ACSCC
ACXBN
ACXME
ACXQS
ADAWD
ADBBV
ADBTR
ADDAD
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADXAS
ADZCM
ADZMN
AEEZP
AEGXH
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFEBI
AFFPM
AFGKR
AFPWT
AFVGU
AFZJQ
AGJLS
AHBTC
AHEFC
AHMBA
AIACR
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AMBMR
AMYDB
ASPBG
ATUGU
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BSCLL
BY8
C45
CAG
COF
CS3
D-6
D-7
D-E
D-F
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DTERQ
DU5
EAD
EAP
EAS
EBC
EBD
EBS
EBX
EJD
EMB
EMK
EMOBN
EPT
ESX
EX3
F00
F01
F04
F5P
FEDTE
FUBAC
FZ0
G-S
G.N
GODZA
H.X
HF~
HVGLF
HZI
HZ~
IHE
IX1
J0M
K48
KBYEO
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
O66
O9-
OVD
P2W
P2X
P2Z
P4B
P4D
PALCI
PQQKQ
Q.N
Q11
QB0
Q~Q
R.K
RIWAO
RJQFR
ROL
RX1
SAMSI
SUPJJ
SV3
TEORI
TUS
UB1
V8K
W8V
W99
WBKPD
WHWMO
WIH
WIJ
WIK
WOHZO
WOW
WQJ
WRC
WUP
WVDHM
WXI
WXSBR
XG1
YFH
YUY
ZZTAW
~IA
~WT
AITYG
HGLYW
OIG
CGR
CUY
CVF
ECM
EIF
NPM
7X8
7U9
H94
ID FETCH-LOGICAL-i3343-a5b21e14dfa3b62d92c5f53440f9f95142300dff965ead1d077fa183f03d85063
IEDL.DBID DR2
ISSN 1352-0504
IngestDate Fri Aug 16 01:11:22 EDT 2024
Thu Aug 15 22:31:03 EDT 2024
Sat Sep 28 07:46:22 EDT 2024
Sat Aug 24 00:48:31 EDT 2024
Wed Jan 17 05:04:15 EST 2024
IsPeerReviewed true
IsScholarly true
Issue 9
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-i3343-a5b21e14dfa3b62d92c5f53440f9f95142300dff965ead1d077fa183f03d85063
Notes ArticleID:JVH1223
istex:D6E4D90D2A94F6A2AA688C4A3BAFA61A1AD387CD
ark:/67375/WNG-F5F4FZQV-H
See composition in
Appendix
.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Article-2
ObjectType-Feature-1
PMID 20002565
PQID 748927697
PQPubID 23479
PageCount 11
ParticipantIDs proquest_miscellaneous_754896384
proquest_miscellaneous_748927697
pubmed_primary_20002565
wiley_primary_10_1111_j_1365_2893_2009_01223_x_JVH1223
istex_primary_ark_67375_WNG_F5F4FZQV_H
PublicationCentury 2000
PublicationDate September 2010
PublicationDateYYYYMMDD 2010-09-01
PublicationDate_xml – month: 09
  year: 2010
  text: September 2010
PublicationDecade 2010
PublicationPlace Oxford, UK
PublicationPlace_xml – name: Oxford, UK
– name: England
PublicationTitle Journal of viral hepatitis
PublicationTitleAlternate J Viral Hepat
PublicationYear 2010
Publisher Blackwell Publishing Ltd
Publisher_xml – name: Blackwell Publishing Ltd
References Anastos K, Schneider MF, Gange SJ et al. The association of race, sociodemographic, and behavioral characteristics with response to highly active antiretroviral therapy in women. J Acquir Immune Defic Syndr 2005; 39(5): 537-544.
Kraus MR, Schafer A, Faller H, Csef H, Scheurlen M. Psychiatric symptoms in patients with chronic hepatitis C receiving interferon alfa-2b therapy. J Clin Psychiatry 2003; 64(6): 708-714.
Bruce RD, Altice FL, Gourevitch MN, Friedland GH. Pharmacokinetic drug interactions between opioid agonist therapy and antiretroviral medications: implications and management for clinical practice. J Acquir Immune Defic Syndr 2006; 5: 563-572.
Fleming CA, Christiansen D, Nunes D et al. Health-related quality of life of patients with HIV disease: impact of hepatitis C coinfection. Clin Infect Dis 2004; 4: 572-578.
Carrico AW, Johnson MO, Morin SF et al. Correlates of suicidal ideation among HIV-positive persons. AIDS 2007; 21(9): 1199-1203.
Voss JG. Predictors and Correlates of Fatigue in HIV/AIDS. J Pain Symptom Manage 2005; 29(2): 173-184.
Gama H, Correia S, Lunet N. Questionnaire design and the recall of pharmacological treatments: a systematic review. Pharmacoepidemiol Drug Saf 2009; 18(3): 175-187.
Starace F, Ammassari A, Trotta MP et al. Depression is a risk factor for suboptimal adherence to highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2002; 31 (Suppl. 3): S136-S139.
Ferrando S, Evans S, Goggin K, Sewell M, Fishman B, Rabkin J. Fatigue in HIV illness: relationship to depression, physical limitations, and disability. Psychosom Med 1998; 60(6): 759-764.
Cook JA, Grey D, Burke-Miller J et al. Effects of treated and untreated depressive symptoms on highly active antiretroviral therapy use in a US multi-site cohort of HIV-positive women. AIDS Care 2006; 18(2): 93-100.
Dimsdale JE, Norman D, DeJardin D, Wallace MS. The effect of opioids on sleep architecture. J Clin Sleep Med 2007; 3(1): 33-36.
Zehnter E. Treatment of Chronic Hepatitis C With Peginterferon alfa-2a (PEG) and Ribavirin (RBV) in Patients With HIV Coinfection in the Real-Life Setting in Germany. Boston: AASLD meeting, 2007; 37(1): 95-100.
Sullivan PS, Dworkin MS. Prevalence and correlates of fatigue among persons with HIV infection. J Pain Symptom Manage 2003; 25(4): 329-333.
Himelhoch S, Medoff DR. Efficacy of antidepressant medication among HIV-positive individuals with depression: a systematic review and meta-analysis. AIDS Patient Care STDS. 2005; 19(12): 813-822.
Castera L, Constant A, Bernard PH, De Ledinghen V, Couzigou P. Lifestyle changes and beliefs regarding disease severity in patients with chronic hepatitis C. J Viral Hepat 2006; 13(7): 482-488.
Henderson M, Safa F, Easterbrook P, Hotopf M. Fatigue among HIV-infected patients in the era of highly active antiretroviral therapy. HIV Med 2005; 6(5): 347-352.
Thein H, Maruff P, Krahn M et al. Cognitive function, mood and health-related quality of life in hepatitis C virus (HCV)-monoinfected and HIV/HCV-coinfected individuals commencing HCV treatment. HIV Med 2007; 8(3): 192-202.
Henry C, Demotes-Mainard J. Avoiding drug-induced switching in patients with bipolar depression. Drug Saf 2003; 26(5): 337-351.
Bonkovsky HL, Snow KK, Malet PF et al. Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis. J Hepatol 2007; 46(3): 420-431.
Sandrin L, Fourquet B, Hasquenoph JM et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003; 29(12): 1705-1713.
Ward DJ, Curtin JM. Switch from efavirenz to nevirapine associated with resolution of efavirenz-related neuropsychiatric adverse events and improvement in lipid profiles. AIDS Patient Care STDS. 2006; 20(8): 542-548.
Golub ET, Latka M, Hagan H et al. Screening for depressive symptoms among HCV-infected injection drug users: examination of the utility of the CES-D and the beck depression inventory. J Urban Health 2004; 81(2): 278-290.
Fumaz CR, Munoz-Moreno JA, Ballesteros AL et al. Influence of the type of pegylated interferon on the onset of depressive and neuropsychiatric symptoms in HIV-HCV coinfected patients. AIDS Care 2007; 19(1): 138-145.
Bonkovsky HL, Woolley JM. Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy.The Consensus Interferon Study Group. Hepatology 1999; 29(1): 264-270.
Protopopescu C, Marcellin F, Spire B et al. Health-related quality of life in HIV-1-infected patients on HAART: a five-years longitudinal analysis accounting for dropout in the APROCO-COPILOTE cohort (ANRS CO-8). Qual Life Res 2007; 16(4): 577-591.
Fairfield KM, Libman H, Davis RB, Eisenberg DM. Delays in protease inhibitor use in clinical practice. J Gen Intern Med 1999; 14(7): 395-401.
Pence BW, Miller WC, Whetten K, Eron JJ, Gaynes BN. Prevalence of DSM-IV-defined mood, anxiety, and substance use disorders in an HIV clinic in the Southeastern United States. J Acquir Immune Defic Syndr 2006; 42(3): 298-306.
Foster GR, Goldin RD, Thomas HC. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology 1998; 27(1): 209-212.
Gutteling JJ, De Man RA, Van Der Plas SM, Schalm SW, Busschbach JJ, Darlington AS. Determinants of quality of life in chronic liver patients. Aliment Pharmacol Ther 2006; 11: 1629-1635.
Ridge G, Gossop M, Lintzeris N, Witton J, Strang J. Factors associated with the prescribing of buprenorphine or methadone for treatment of opiate dependence. J Subst Abuse Treat 2008; 37(1): 95-100.
Braitstein P, Montessori V, Chan K et al. Quality of life, depression and fatigue among persons co-infected with HIV and hepatitis C: outcomes from a population-based cohort. AIDS Care 2005; 17(4): 505-515.
Gupta SK, Sellers E, Somoza E, Angles L, Kolz K, Cutler DL. The effect of multiple doses of peginterferon alfa-2b on the steady-state pharmacokinetics of methadone in patients with chronic hepatitis C undergoing methadone maintenance therapy. J Clin Pharmacol 2007; 47(5): 604-612.
Constant A, Castera L, Dantzer R et al. Mood alterations during interferon-alfa therapy in patients with chronic hepatitis C: evidence for an overlap between manic/hypomanic and depressive symptoms. J Clin Psychiatry 2005; 66(8): 1050-1057.
Benyamin R, Trescot AM, Datta S et al. Opioid complications and side effects. Pain Physician 2008; 11 (Suppl. 2): S105-S120.
Breitbart W, McDonald MV, Rosenfeld B, Monkman ND, Passik S. Fatigue in ambulatory AIDS patients. J Pain Symptom Manage 1998; 15(3): 159-167.
Spire B, Carrieri P, Garzot MA, L'Henaff M, Obadia Y. Factors associated with efavirenz discontinuation in a large community-based sample of patients. AIDS Care 2004; 16(5): 558-564.
Nelder JA, Wedderburn RWM. Generalized linear models. J Roy Stat Soc 1972; 135: 370-384.
Duran S, Spire B, Raffi F et al. Self-reported symptoms after initiation of a protease inhibitor in HIV-infected patients and their impact on adherence to HAART. HIV Clin Trials 2001; 2(1): 38-45.
Kallman J, O'Neil MM, Larive B, Boparai N, Calabrese L, Younossi ZM. Fatigue and health-related quality of life (HRQL) in chronic hepatitis C virus infection. Dig Dis Sci 2007; 52(10): 2531-2539.
Marcellin F, Preau M, Ravaux I, Dellamonica P, Spire B, Carrieri MP. Self-reported fatigue and depressive symptoms as main indicators of the quality of life (QOL) of patients living with HIV and Hepatitis C: implications for clinical management and future research. HIV Clin Trials 2007; 8(5): 320-327.
Daniell HW. DHEAS deficiency during consumption of sustained-action prescribed opioids: evidence for opioid-induced inhibition of adrenal androgen production. J Pain 2006; 7(12): 901-907.
Fisk JD, Ritvo PG, Ross L, Haase DA, Marrie TJ, Schlech WF. Measuring the functional impact of fatigue: initial validation of the fatigue impact scale. Clin Infect Dis 1994; 18 (Suppl. 1): S79-S83.
Raison CL, Borisov AS, Broadwell SD et al. Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction. J Clin Psychiatry 2005; 66(1): 41-48.
Clifford DB, Evans SR, Yang Y, Gulick RM. The neuropsychological and neurological impact of hepatitis C virus co-infection in HIV-infected subjects. AIDS 2005; 19 (Suppl. 3): S64-S71.
Katz MH, Douglas JM Jr, Bolan GA et al. Depression and use of mental health services among HIV-infected men. AIDS Care 1996; 8(4): 433-442.
Bouhnik AD, Preau M, Vincent E et al. Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy. Antivir Ther 2005; 10(1): 53-61.
APA. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). 4th edn. Washington, DC: APA, 1994.
Mauss S. Treatment of viral hepatitis in HIV-coinfected patients-adverse events and their management. J Hepatol 2006; 44 (Suppl. 1): S114-S118.
Poynard T, Cacoub P, Ratziu V et al. Fatigue in patients with chronic hepatitis C. J Viral Hepat 2002; 9(4): 295-303.
Carrieri MP, Villes V, Raffi F et al. Self-reported side-effects of anti-retroviral treatment among IDUs: a 7-year longitudinal study (APROCO-COPILOTE COHORT ANRS CO-8). Int J Drug Policy 2007; 18(4): 288-295.
Cotterchio M, Kreiger N, Darlington G, Steingart A. Comparison of self-reported and physician-reported antidepressant medication use. Ann Epidemiol 1999; 9(5): 283-289.
Gohier B, Goeb JL, Rannou-Dubas K, Fouchard I, Cales P, Garre JB. Hepatitis C, alpha interferon, anxiety and depression disorders: a prospective study of 71 patients. World J Biol Psychiatry 2003; 4(3): 115-118.
Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001; 357(9262): 1069-1075.
Fuhrer R, Rouillon F. La version française de l'échelle CES-D. Description and translation of the autoevaluation scale (in French). Psychiatrie et Psychobiologie 1989; 4: 163-166.
Barroso J, Lynn MR. Psychometric properties of the HIV-Related Fatigue Sca
2002; 13
2004; 4
2008; 37
2008; 6
1972; 135
2005; 29
2007; 34
2005; 66
2007; 37
1998; 15
2006; 20
2008; 29
1999; 14
2007; 8
2003; 4
2007; 3
2007; 21
2005; 39
1996; 8
2009; 18
2001; 54
1998; 27
2007; 18
2007; 19
1989; 4
2004; 81
2002; 9
2006; 13
2002; 31
1999; 29
2006; 11
2006; 7
2006; 18
2006; 5
1994
2008; 11
2001; 28
1998; 60
2007; 52
2007; 12
1999; 9
2007; 16
2005; 19
2006; 42
2004; 16
2006; 44
2005; 9
2003; 25
2003; 26
2005; 6
2005; 10
2003; 29
2001; 2
1994; 18
2005; 17
2001; 357
2003; 64
2007; 46
2007; 47
References_xml – volume: 19
  start-page: 813
  issue: 12
  year: 2005
  end-page: 822
  article-title: Efficacy of antidepressant medication among HIV‐positive individuals with depression: a systematic review and meta‐analysis
  publication-title: AIDS Patient Care STDS.
– volume: 3
  start-page: 33
  issue: 1
  year: 2007
  end-page: 36
  article-title: The effect of opioids on sleep architecture
  publication-title: J Clin Sleep Med
– volume: 66
  start-page: 1050
  issue: 8
  year: 2005
  end-page: 1057
  article-title: Mood alterations during interferon‐alfa therapy in patients with chronic hepatitis C: evidence for an overlap between manic/hypomanic and depressive symptoms
  publication-title: J Clin Psychiatry
– volume: 39
  start-page: 537
  issue: 5
  year: 2005
  end-page: 544
  article-title: The association of race, sociodemographic, and behavioral characteristics with response to highly active antiretroviral therapy in women
  publication-title: J Acquir Immune Defic Syndr
– volume: 37
  start-page: 95
  issue: 1
  year: 2008
  end-page: 100
  article-title: Factors associated with the prescribing of buprenorphine or methadone for treatment of opiate dependence
  publication-title: J Subst Abuse Treat
– volume: 135
  start-page: 370
  year: 1972
  end-page: 384
  article-title: Generalized linear models
  publication-title: J Roy Stat Soc
– volume: 37
  start-page: 95
  issue: 1
  year: 2007
  end-page: 100
– volume: 42
  start-page: 298
  issue: 3
  year: 2006
  end-page: 306
  article-title: Prevalence of DSM‐IV‐defined mood, anxiety, and substance use disorders in an HIV clinic in the Southeastern United States
  publication-title: J Acquir Immune Defic Syndr
– volume: 18
  start-page: S79
  issue: Suppl. 1
  year: 1994
  end-page: S83
  article-title: Measuring the functional impact of fatigue: initial validation of the fatigue impact scale
  publication-title: Clin Infect Dis
– volume: 29
  start-page: 617
  issue: 4
  year: 2008
  end-page: 630
  article-title: CTN‐194 (PICCO): design of a trial of citalopram for the prevention of depression and its consequences in HIV‐Hepatitis C co‐infected individuals initiating pegylated interferon/ribavirin therapy
  publication-title: Contemp Clin Trials
– volume: 16
  start-page: 577
  issue: 4
  year: 2007
  end-page: 591
  article-title: Health‐related quality of life in HIV‐1‐infected patients on HAART: a five‐years longitudinal analysis accounting for dropout in the APROCO‐COPILOTE cohort (ANRS CO‐8)
  publication-title: Qual Life Res
– volume: 60
  start-page: 759
  issue: 6
  year: 1998
  end-page: 764
  article-title: Fatigue in HIV illness: relationship to depression, physical limitations, and disability
  publication-title: Psychosom Med
– volume: 4
  start-page: 163
  year: 1989
  end-page: 166
  article-title: La version française de l’échelle CES‐D. Description and translation of the autoevaluation scale (in French)
  publication-title: Psychiatrie et Psychobiologie
– volume: 29
  start-page: 1705
  issue: 12
  year: 2003
  end-page: 1713
  article-title: Transient elastography: a new noninvasive method for assessment of hepatic fibrosis
  publication-title: Ultrasound Med Biol
– volume: 9
  start-page: 295
  issue: 4
  year: 2002
  end-page: 303
  article-title: Fatigue in patients with chronic hepatitis C
  publication-title: J Viral Hepat
– volume: 28
  start-page: 445
  issue: 5
  year: 2001
  end-page: 449
  article-title: Self‐Reported Symptoms and Medication Side Effects Influence Adherence to Highly Active Antiretroviral Therapy in Persons With HIV Infection
  publication-title: J Acquir Immune Defic Syndr
– volume: 19
  start-page: S64
  issue: Suppl. 3
  year: 2005
  end-page: S71
  article-title: The neuropsychological and neurological impact of hepatitis C virus co‐infection in HIV‐infected subjects
  publication-title: AIDS
– volume: 20
  start-page: 542
  issue: 8
  year: 2006
  end-page: 548
  article-title: Switch from efavirenz to nevirapine associated with resolution of efavirenz‐related neuropsychiatric adverse events and improvement in lipid profiles
  publication-title: AIDS Patient Care STDS.
– year: 1994
– volume: 10
  start-page: 53
  issue: 1
  year: 2005
  end-page: 61
  article-title: Depression and clinical progression in HIV‐infected drug users treated with highly active antiretroviral therapy
  publication-title: Antivir Ther
– volume: 8
  start-page: 192
  issue: 3
  year: 2007
  end-page: 202
  article-title: Cognitive function, mood and health‐related quality of life in hepatitis C virus (HCV)‐monoinfected and HIV/HCV‐coinfected individuals commencing HCV treatment
  publication-title: HIV Med
– volume: 7
  start-page: 901
  issue: 12
  year: 2006
  end-page: 907
  article-title: DHEAS deficiency during consumption of sustained‐action prescribed opioids: evidence for opioid‐induced inhibition of adrenal androgen production
  publication-title: J Pain
– volume: 7
  start-page: 544
  issue: 8
  year: 2006
  end-page: 548
  article-title: Efavirenz and chronic neuropsychiatric symptoms: a cross‐sectional case control study
  publication-title: HIV Med
– volume: 8
  start-page: 433
  issue: 4
  year: 1996
  end-page: 442
  article-title: Depression and use of mental health services among HIV‐infected men
  publication-title: AIDS Care
– volume: 19
  start-page: 138
  issue: 1
  year: 2007
  end-page: 145
  article-title: Influence of the type of pegylated interferon on the onset of depressive and neuropsychiatric symptoms in HIV‐HCV coinfected patients
  publication-title: AIDS Care
– volume: 29
  start-page: 264
  issue: 1
  year: 1999
  end-page: 270
  article-title: Reduction of health‐related quality of life in chronic hepatitis C and improvement with interferon therapy.The Consensus Interferon Study Group
  publication-title: Hepatology
– volume: 12
  start-page: 1067
  issue: 7
  year: 2007
  end-page: 1074
  article-title: The effect of depressive symptoms at ART initiation on HIV clinical progression and mortality: implications in clinical practice
  publication-title: Antivir Ther
– volume: 4
  start-page: 115
  issue: 3
  year: 2003
  end-page: 118
  article-title: Hepatitis C, alpha interferon, anxiety and depression disorders: a prospective study of 71 patients
  publication-title: World J Biol Psychiatry
– volume: 21
  start-page: 1199
  issue: 9
  year: 2007
  end-page: 1203
  article-title: Correlates of suicidal ideation among HIV‐positive persons
  publication-title: AIDS
– volume: 26
  start-page: 337
  issue: 5
  year: 2003
  end-page: 351
  article-title: Avoiding drug‐induced switching in patients with bipolar depression
  publication-title: Drug Saf
– volume: 8
  start-page: 320
  issue: 5
  year: 2007
  end-page: 327
  article-title: Self‐reported fatigue and depressive symptoms as main indicators of the quality of life (QOL) of patients living with HIV and Hepatitis C: implications for clinical management and future research
  publication-title: HIV Clin Trials
– volume: 81
  start-page: 278
  issue: 2
  year: 2004
  end-page: 290
  article-title: Screening for depressive symptoms among HCV‐infected injection drug users: examination of the utility of the CES‐D and the beck depression inventory
  publication-title: J Urban Health
– volume: 31
  start-page: S136
  issue: Suppl. 3
  year: 2002
  end-page: S139
  article-title: Depression is a risk factor for suboptimal adherence to highly active antiretroviral therapy
  publication-title: J Acquir Immune Defic Syndr
– volume: 64
  start-page: 708
  issue: 6
  year: 2003
  end-page: 714
  article-title: Psychiatric symptoms in patients with chronic hepatitis C receiving interferon alfa‐2b therapy
  publication-title: J Clin Psychiatry
– volume: 14
  start-page: 395
  issue: 7
  year: 1999
  end-page: 401
  article-title: Delays in protease inhibitor use in clinical practice
  publication-title: J Gen Intern Med
– volume: 13
  start-page: 482
  issue: 7
  year: 2006
  end-page: 488
  article-title: Lifestyle changes and beliefs regarding disease severity in patients with chronic hepatitis C
  publication-title: J Viral Hepat
– volume: 18
  start-page: 288
  issue: 4
  year: 2007
  end-page: 295
  article-title: Self‐reported side‐effects of anti‐retroviral treatment among IDUs: a 7‐year longitudinal study (APROCO‐COPILOTE COHORT ANRS CO‐8)
  publication-title: Int J Drug Policy
– volume: 4
  start-page: 572
  year: 2004
  end-page: 578
  article-title: Health‐related quality of life of patients with HIV disease: impact of hepatitis C coinfection
  publication-title: Clin Infect Dis
– volume: 25
  start-page: 329
  issue: 4
  year: 2003
  end-page: 333
  article-title: Prevalence and correlates of fatigue among persons with HIV infection
  publication-title: J Pain Symptom Manage
– volume: 17
  start-page: 505
  issue: 4
  year: 2005
  end-page: 515
  article-title: Quality of life, depression and fatigue among persons co‐infected with HIV and hepatitis C: outcomes from a population‐based cohort
  publication-title: AIDS Care
– volume: 11
  start-page: S105
  issue: Suppl. 2
  year: 2008
  end-page: S120
  article-title: Opioid complications and side effects
  publication-title: Pain Physician
– volume: 15
  start-page: 159
  issue: 3
  year: 1998
  end-page: 167
  article-title: Fatigue in ambulatory AIDS patients
  publication-title: J Pain Symptom Manage
– volume: 18
  start-page: 93
  issue: 2
  year: 2006
  end-page: 100
  article-title: Effects of treated and untreated depressive symptoms on highly active antiretroviral therapy use in a US multi‐site cohort of HIV‐positive women
  publication-title: AIDS Care
– volume: 66
  start-page: 41
  issue: 1
  year: 2005
  end-page: 48
  article-title: Depression during pegylated interferon‐alpha plus ribavirin therapy: prevalence and prediction
  publication-title: J Clin Psychiatry
– volume: 47
  start-page: 604
  issue: 5
  year: 2007
  end-page: 612
  article-title: The effect of multiple doses of peginterferon alfa‐2b on the steady‐state pharmacokinetics of methadone in patients with chronic hepatitis C undergoing methadone maintenance therapy
  publication-title: J Clin Pharmacol
– volume: 46
  start-page: 420
  issue: 3
  year: 2007
  end-page: 431
  article-title: Health‐related quality of life in patients with chronic hepatitis C and advanced fibrosis
  publication-title: J Hepatol
– volume: 34
  start-page: 413
  issue: 4
  year: 2007
  end-page: 421
  article-title: Adding HCV treatment to HIV treatment in HIV‐HCV coinfected patients: the impact on the different dimensions of fatigue and self‐reported side effects
  publication-title: J Pain Symptom Manage
– volume: 27
  start-page: 209
  issue: 1
  year: 1998
  end-page: 212
  article-title: Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis
  publication-title: Hepatology
– volume: 9
  start-page: 239
  issue: 4
  year: 2005
  end-page: 242
  article-title: The management of opioid‐related sedation
  publication-title: Curr Pain Headache Rep
– volume: 6
  start-page: 557
  year: 2008
  end-page: 562
  article-title: Subjective daytime sleepiness and daytime function in patients on stable methadone maintenance treatment: possible mechanisms
  publication-title: J Clin Sleep Med
– volume: 6
  start-page: 347
  issue: 5
  year: 2005
  end-page: 352
  article-title: Fatigue among HIV‐infected patients in the era of highly active antiretroviral therapy
  publication-title: HIV Med
– volume: 18
  start-page: 175
  issue: 3
  year: 2009
  end-page: 187
  article-title: Questionnaire design and the recall of pharmacological treatments: a systematic review
  publication-title: Pharmacoepidemiol Drug Saf
– volume: 13
  start-page: 66
  issue: 1
  year: 2002
  end-page: 75
  article-title: Psychometric properties of the HIV‐Related Fatigue Scale
  publication-title: J Assoc Nurses AIDS Care
– volume: 5
  start-page: 563
  year: 2006
  end-page: 572
  article-title: Pharmacokinetic drug interactions between opioid agonist therapy and antiretroviral medications: implications and management for clinical practice
  publication-title: J Acquir Immune Defic Syndr
– volume: 52
  start-page: 2531
  issue: 10
  year: 2007
  end-page: 2539
  article-title: Fatigue and health‐related quality of life (HRQL) in chronic hepatitis C virus infection
  publication-title: Dig Dis Sci
– volume: 11
  start-page: 1629
  year: 2006
  end-page: 1635
  article-title: Determinants of quality of life in chronic liver patients
  publication-title: Aliment Pharmacol Ther
– volume: 29
  start-page: 173
  issue: 2
  year: 2005
  end-page: 184
  article-title: Predictors and Correlates of Fatigue in HIV/AIDS
  publication-title: J Pain Symptom Manage
– volume: 44
  start-page: S114
  issue: Suppl. 1
  year: 2006
  end-page: S118
  article-title: Treatment of viral hepatitis in HIV‐coinfected patients‐adverse events and their management
  publication-title: J Hepatol
– volume: 2
  start-page: 38
  issue: 1
  year: 2001
  end-page: 45
  article-title: Self‐reported symptoms after initiation of a protease inhibitor in HIV‐infected patients and their impact on adherence to HAART
  publication-title: HIV Clin Trials
– volume: 9
  start-page: 283
  issue: 5
  year: 1999
  end-page: 289
  article-title: Comparison of self‐reported and physician‐reported antidepressant medication use
  publication-title: Ann Epidemiol
– volume: 357
  start-page: 1069
  issue: 9262
  year: 2001
  end-page: 1075
  article-title: Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study
  publication-title: Lancet
– volume: 54
  start-page: S77
  issue: Suppl. 1
  year: 2001
  end-page: S90
  article-title: Development and validation of a self‐completed HIV symptom index
  publication-title: J Clin Epidemiol
– volume: 16
  start-page: 558
  issue: 5
  year: 2004
  end-page: 564
  article-title: Factors associated with efavirenz discontinuation in a large community‐based sample of patients
  publication-title: AIDS Care
SSID ssj0013251
Score 2.0397203
Snippet Fatigue is a major component of quality of life (QOL) and is associated with depression in HIV–HCV co‐infected individuals. We investigated whether treating...
Fatigue is a major component of quality of life (QOL) and is associated with depression in HIV-HCV co-infected individuals. We investigated whether treating...
SourceID proquest
pubmed
wiley
istex
SourceType Aggregation Database
Index Database
Publisher
StartPage 650
SubjectTerms Adult
Antidepressive Agents - therapeutic use
CD4 antigen
Cognitive ability
Data collections
Data processing
Depression
Depression - drug therapy
Fatigue
Fatigue - drug therapy
Female
France
Hepatitis
hepatitis C
Hepatitis C, Chronic - complications
HIV Infections - complications
Human immunodeficiency virus
Humans
Infection
Inventories
Male
medical records
Middle Aged
Quality of life
Surveys and Questionnaires
Treatment Outcome
Title Role of treatment for depressive symptoms in relieving the impact of fatigue in HIV-HCV co-infected patients: ANRS Co13 Hepavih, France, 2006-2008
URI https://api.istex.fr/ark:/67375/WNG-F5F4FZQV-H/fulltext.pdf
https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fj.1365-2893.2009.01223.x
https://www.ncbi.nlm.nih.gov/pubmed/20002565
https://search.proquest.com/docview/748927697
https://search.proquest.com/docview/754896384
Volume 17
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQJRAXHuXRhYJ8QJyaVeJHQrhVK0Ko1JVY6FJxsZzYhtW2SbXZrVpO_QmVuPD7-kuYibOrLqo4IG6RYuf5jf3N-JsxIa8ANAUX2gRAlS04KG2ysuGBsA7IhXEsKjAOuT-M8wOxdygPO_0T5sL4-hCrgBtaRjteo4Hrolk38lahBRNuV3Yygqmuj3wS6-ohPxqxawsK0vtekgWhDMW6qOfGCwFdxS99dhP3XKey7VyU3SfT5Vt4Ccq0v5gX_fLHHwUe_89rPiD3OspKdz3GHpJbttokt_0mlueb5M5-tzz_iPwa1UeW1o6u5OsUODFdqm1PLW3Oj0_m9XFDJxWdwZNZjGdQIKHUp2tiZwdg-baw2CT_ML66-JkPxrSsry4uvXLMGtpVg23e0t3h6BMd1BGnOUysp5PvO7TdK8TuUAxjQG-UXjwmB9m7z4M86LZ-CCacCx5oWbDIRsI4zYuYmZSVEsAjROhSB6QQSGAYGufSWIIpRCZMEqdhdHIhN1iDjz8hG1Vd2S1CeRqaUiTaCZGIIoo1Y0XJuJZJKewbzXrkdfub1Ykv76H0bIpqt0SqL8P3KpOZyL5-HKu8R-gSBwpsEBdWdGXrRaOwgg9L4jT5SxPwDHGsEz3y1ENodT9MlgLiKXskboGwOnHNPwMIKIQANk5VCwF1pvbGOR49-9eOz8ldL4ZAydw22ZjPFvYFcKx58bK1nt_lARiO
link.rule.ids 315,786,790,1382,27957,27958,46329,46753
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQEY9LgULp8vQBcWpWiR8J4VatWNLSXYmlXSouVhLbsGqbVPuoWk79CUhc-H39JczY2VUXVRwQt0ix8_zG_mb8zZiQVwCagotcB0CVDTgoLllZ80AYC-RCWxYVGIfs9eNsX-wcyINmOyDMhfH1IRYBN7QMN16jgWNAetnKnUQLZtym7mQEc10bCOVNsH7p_KsBu7KkIL33JVkQylAsy3quvRIQVvzWZ9exz2Uy62aj7j1yNH8PL0I5bM-mRbv8_keJx__0ovfJasNa6ZaH2QNyw1Rr5Jbfx_J8jdzuNSv0D8mvQX1kaG3pQsFOgRbTueD21NDJ-fHJtD6e0FFFx_BoBkMaFHgo9Rmb2NkCXr7ODDbJtoeXFz-zzpCW9eXFDy8eM5o2BWEnb-lWf_CJduqI0wzm1tPRt03qtgsxmxQjGdAb1RePyH733V4nC5rdH4IR54IHuSxYZCKhbc6LmOmUlRLwI0RoUwu8EHhgGGpr01iCNUQ6TBKbwwBlQ66xDB9fJytVXZkNQnka6lIkuRUiEUUU54wVJeO5TEph3uSsRV67_6xOfIUPlY8PUfCWSPW5_151ZVd0v3wcqqxF6BwICswQ11byytSzicIiPiyJ0-QvTcA5xOFOtMhjj6HF_TBfCrinbJHYIWFx4oqLBhBQCAFsnCoHAXWmdoYZHj35144vyZ1sr7erdrf7H56Su14bgQq6Z2RlOp6Z50C5psULZ0q_AYduHLA
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQERUXHuW1PH1AnJpV4kdCuFVbQlroCha6VL1YTmzDaulmtY-q5dSfgMSF39dfwkycXXVRxQFxixQ7z2_sb8bfjAl5DqApuNAmAKpswUGpk5UND4R1QC6MY1GBcci9bpzvi90DedDonzAXxteHWAbc0DLq8RoNfGzcqpHXCi2YcJuykxFMdW3gk1dFzBkifLvHLqwoSO98SRaEMhSrqp5LrwR8FT_1yWXkc5XL1pNRdpMMF6_hNSjD9nxWtMvvf1R4_D_veYvcaDgr3fIgu02u2NEGueZ3sTzdIOt7zfr8HfKrV32ztHJ0qV-nQIrpQm57bOn09Gg8q46mdDCiE3gyiwENCiyU-nxN7OwALV_mFpvkO_3zs595p0_L6vzsh5eOWUObcrDTV3Sr2_tIO1XEaQ4z6_Hg6yatNwuxmxTjGNAbtRd3yX72-lMnD5q9H4IB54IHWhYsspEwTvMiZiZlpQT0CBG61AErBBYYhsa5NJZgC5EJk8RpGJ5cyA0W4eP3yNqoGtkHhPI0NKVItBMiEUUUa8aKknEtk1LYl5q1yIv6N6uxr--h9GSIcrdEqs_dNyqTmcgOP_RV3iJ0gQMFRogrK3pkq_lUYQkflsRp8pcm4BriYCda5L6H0PJ-mC0FzFO2SFwDYXnigoMGEFAIAWycqhoC6kTt9nM8evivHZ-R9ffbmXq30337iFz3wgiUzz0ma7PJ3D4BvjUrntaG9BsL-xtf
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Role+of+treatment+for+depressive+symptoms+in+relieving+the+impact+of+fatigue+in+HIV-HCV+co-infected+patients%3A+ANRS+Co13+Hepavih%2C+France%2C+2006-2008&rft.jtitle=Journal+of+viral+hepatitis&rft.au=Michel%2C+L&rft.au=Villes%2C+V&rft.au=Dabis%2C+F&rft.au=Spire%2C+B&rft.date=2010-09-01&rft.issn=1352-0504&rft.volume=17&rft.issue=9&rft.spage=650&rft.epage=660&rft_id=info:doi/10.1111%2Fj.1365-2893.2009.01223.x&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1352-0504&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1352-0504&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1352-0504&client=summon